ICG318 not checked

iCell Gene Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
3 active
3 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Inflammatory Bowel Diseases (IBD), Inflammatory Myopathy
Main trialPhase 2
“This Phase IIa, open-label, single-arm study includes an initial Safety Run-In followed by dose expansion to evaluate the safety, tolerability, cellular kinetics, pharmacodynamics, and preliminary clinical activity of a single infusion of ICG318 in participants with refractory SLE, with or without LN. Participants will receive protocol-specified lymphodepletion followed by ICG318 at the recommended Phase 2 dose.”In the company’s words, NCT07328581 on ClinicalTrials.gov

Other drugs for Systemic Lupus Erythematosus (SLE)

All 131 drugs for Systemic Lupus Erythematosus (SLE)

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Dec 2028 A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
Phase 1/2Not yet recruiting 7 Apr 2028 BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)
Phase 1Recruiting 31 Dec 2027 BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ICG318

Following is part of Solo: you see every change to ICG318 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in